Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of intravitreal BAT5906 in wet age-related macular degeneration
ChiCTR2000032723Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BAT5906 in exudative macular degeneration (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Full analysis set, Per protocol set and 4 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
BAT5906
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2000032723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032723.